Page 1547 - Williams Hematology ( PDFDrive )

1522 Part XI: Malignant Lymphoid Diseases Chapter 91: Acute Lymphoblastic Leukemia 1523

23. SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD, 58. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood acute
http://seer.cancer.gov/csr/1975_2010. Accessed July 4, 2014. lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification
24. Sandler DP, Ross JA: Epidemiology of acute leukemia in children and adults. Semin study. Lancet Oncol 10:125, 2009.
Oncol 24:3, 1997. 59. Harvey RC, Mullighan CG, Wang X, et al: Identification of novel cluster groups in
25. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression
GLOBOCAN 2008. Int J Cancer 127:2893, 2010. profiling: Correlation with genome-wide DNA copy number alterations, clinical char-
26. Forestier E, Izraeli S, Beverloo B, et al: Cytogenetic features of acute lymphoblastic and acteristics, and outcome. Blood 116; 4874, 2010.
myeloid leukemias in pediatric patients with Down syndrome: An iBFM-SG study. 60. Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2
Blood 111:1575, 2008. in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat
27. Izraeli S, Vora A, Zwaan CM, Whitlock J: How I treat ALL in Down’s syndrome: Patho- Genet 41:1243, 2009.
biology and management. Blood 123:35, 2014. 61. Ferrando AA, Look AT: Gene expression profiling in T-cell acute lymphoblastic leuke-
28. Mullighan CG, Zhang J, Harvey RC, et al: JAK mutations in high-risk childhood acute mia. Semin Hematol 40:274, 2003.
lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414, 2009. 62. Armstrong SA, Kung AL, Mabon ME, et al: Inhibition of FLT3 in MLL: Validation of a
29. Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2 therapeutic target identified by gene expression based classification. Cancer Cell 3:173,
in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat 2003.
Genet 41:1243, 2009. 63. Garcia-Manero G, Yang H, Kuang SQ, et al: Epigenetics of acute lymphoblastic leuke-
30. Hertzberg L, Vendramini E, Ganmore I, et al: Down syndrome acute lymphoblastic mia. Semin Hematol 46:24, 2009.
leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is 64. Geng H, Brennan S, Milne TA, et al: Integrative epigenomic analysis identifies biomark-
associated with mutated JAK2: A report from the International BFM Study Group. ers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov
Blood 115:1006, 2010. 2:1004, 2012.
31. Vanasse GJ, Concannon P, Willerford DM: Regulated genomic instability and neoplasia 65. Pui CH: Acute lymphoblastic leukemia, in Childhood Leukemias, ed 2, edited by Pui
in the lymphoid lineage. Blood 94:3997, 1999. CH, p 439. Cambridge University Press, New York, 2006.
32. Liberzon E, Avigad S, Stark B, et al: Germ-line ATM gene alterations are associated 66. Freedman AS, Aster JC: Clinical manifestations, pathologic features, and diagnosis of
with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes precursor B-cell acute lymphoblastic leukemia/lymphoma, in UpToDate, edited by Post
Chromosomes Cancer 39:161, 2004. TW. UpToDate, Waltham, MA. http://www.uptodate.com/contents/clinical-manifesta-
33. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al: Loci on 7p12.2, 10q21.2 and tions-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leu-
14q11. 2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet kemia-lymphoma. (Accessed on August 07, 2015.)
41:1006–1010, 2009. 67. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with
34. Trevino LR, Yang W, French D, et al: Germline genomic variants associated with child- intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leu-
hood acute lymphoblastic leukemia. Nat Genet 41:1001, 2009. kemia Group B study 8811. Blood 85:2025, 1995.
35. Sherborne AL, Hosking FJ, Prasad RB, et al: Variation in CDKN2A at 9p21. 3 influences 68. Pui C-H, Stass S, Green A: Bone marrow necrosis in children with malignant disease.
childhood acute lymphoblastic leukemia risk. Nat Genet 42:492, 2010. Cancer 56:1522, 1985.
36. Yang JJ, Cheng C, Yang W, et al: Genome-wide interrogation of germline genetic vari- 69. Shah NR, Landi DB, Kreissman SG, et al: Presentation and outcomes for children with
ation associated with treatment response in childhood acute lymphoblastic leukemia. bone marrow necrosis and acute lymphoblastic leukemia: A literature review. J Pediatr
JAMA 301:393, 2009. Hematol Oncol 33:e316, 2011.
37. Doll R, Wakeford R: Risk of childhood cancer from fetal irradiation. Br J Radiol 70:130, 70. Lowe EJ, Pui CH, Hancock ML, et al: Early complications in children with acute lympho-
1997. blastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 45:10, 2005.
38. Draper G, Vincent T, Kroll ME, Swanson J: Childhood cancer in relation to distance 71. Hijiya N, Liu W, Sandlund JT, et al: Overt testicular disease at diagnosis of childhood
from high voltage power lines in England and Wales: A case-control study. BMJ acute lymphoblastic leukemia: Lack of therapeutic role of local irradiation. Leukemia
330:1290, 2005. 19:1399, 2005.
39. Sermage-Faure C, Demoury C, Rudant J, et al: Childhood leukaemia close to high-voltage 72. Huang MS, Hasserjian RP: Case 19-2004: A 12-year-old boy with fatigue and eosino-
power lines—The Geocap study, 2002–2007. Br J Cancer 108:1899, 2013. philia. N Engl J Med 350:2604, 2004.
40. Hjalgrim LL, Rostgaard K, Hjalgrim H, et al: Birth weight and risk for childhood leuke- 73. Beutler E: Platelet transfusions: The 20,000/microL trigger. Blood 81:1411, 1993.
mia in Denmark, Sweden, Norway, and Iceland. J Natl Cancer Inst 96:1549, 2004. 74. Slichter SJ: Evidence-based platelet transfusion guidelines. Hematology Am Soc Hema-
41. Inaba H, Greaves M, Mullighan CG: Acute lymphoblastic leukaemia. Lancet 381:1943, tol Educ Program 2007:172, 2007.
2013. 75. Hasle H, Heim S, Schroeder H, et al: Transient pancytopenia preceding acute lympho-
42. Li C, Zhou Y: Association between NQO1 C609T polymorphism and acute lympho- blastic leukemia (pre-ALL). Leukemia 9:605, 1995.
blastic leukemia risk: Evidence from an updated meta-analysis based on 17 case-control 76. Ribeiro RC, Pui CH: The clinical and biological correlates of coagulopathy in children
studies. J Cancer Res Clin Oncol 140:873, 2014. with acute leukemia. J Clin Oncol 4:1212, 1986.
43. Sherborne AL, Hemminki K, Kumar R, et al: Rationale for an international consortium 77. Inukai T, Hirose K, Inaba T, et al: Hypercalcemia in childhood acute lymphoblastic
to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. leukemia: Frequent implication of parathyroid hormone-related peptide and E2A-HLF
Haematologica 96:1049, 2011. from translocation 17;19. Leukemia 21:288, 2007.
44. Trevino LR, Yang W, French D, et al: Germline genomic variants associated with child- 78. Liang R: How I treat and monitor viral hepatitis B infection in patients receiving inten-
hood acute lymphoblastic leukemia. Nat Genet 41:1001, 2009. sive immunosuppressive therapies or undergoing hematopoietic stem cell transplanta-
45. Greaves M: Infection, immune responses and the aetiology of childhood leukaemia. tion. Blood 113:3147, 2009.
Nat Rev Cancer 6:193, 2006. 79. Pui CH, Mahmoud HH, Rivera GK, et al: Early intensification of intrathecal chemo-
46. Maia AT, Tussiwand R, Cazzaniga G, et al: Identification of preleukemic precursors of therapy virtually eliminates central nervous system relapse in children with acute lym-
hyperdiploid acute lymphoblastic leukemia in cord blood. Genes Chromosomes Cancer phoblastic leukemia. Blood 92:411, 1998.
40:38, 2004. 80. Pui CH, Howard SC: Current management and challenges of malignant disease in the
47. Hong D, Gupta R, Ancliff P, et al: Initiating and cancer-propagating cells in TEL-AML1- CNS in paediatric leukaemia. Lancet Oncol 9:257, 2008.
associated childhood leukemia. Science 319:336, 2008. 81. Bürger B, Zimmermann M, Mann G, et al: Diagnostic cerebrospinal fluid examination
48. Kinlen LJ: Infection, immune factors in cancer: The role of epidemiology. Oncogene in children with acute lymphoblastic leukemia: Significance of low leukocyte counts
23:6341, 2004. with blasts or traumatic lumbar puncture. J Clin Oncol 21:184, 2003.
49. Wiemels JL, Leonard BC, Wang Y, et al: Site-specific translocation and evidence of post- 82. Coustan-Smith E, Mullighan CG, Onciu M, et al: Early T-cell precursor leukaemia:
natal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leuke- A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147,
mia. Proc Natl Acad Sci U S A 99:15101, 2002. 2009.
50. Moorman AV, Chilton L, Wilkinson J, et al: A population-based cytogenetic study of 83. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol
adults with acute lymphoblastic leukemia. Blood 115:206, 2010. 46:100, 2009.
51. Mrózek K, Harper DP, Aplan PD: Cytogenetics and molecular genetics of acute lym- 84. Pui CH, Rubnitz JE, Hancock ML, et al: Reappraisal of the clinical and biologic sig-
phoblastic leukemia. Hematol Oncol Clin North Am 23:991, 2009. nificance of myeloid-associated antigen expression in childhood acute lymphoblastic
52. Harrison CJ: Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. leukemia. J Clin Oncol 16:3768, 1998.
Br J Haematol 144:147, 2009. 85. Rubnitz JE, Onciu M, Pounds S, et al: Acute mixed lineage leukemia in children: The
53. Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731, 2001. experience of St. Jude Children’s Research Hospital. Blood 113:5083, 2009.
54. Weng P, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell 86. Neff T, Armstrong SA: Recent progress toward epigenetic therapies: The example of
acute lymphoblastic leukemia. Science 306:269, 2004. mixed lineage leukemia. Blood 121:4847, 2013.
55. Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations 87. Meijerink JP, Den Boer ML, Pieters R: New genetic abnormalities and treatment
in acute lymphoblastic leukemia. Nature 446:758, 2007. response in acute lymphoblastic leukemia. Semin Hematol 46:16, 2009.
56. Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukemia is charac- 88. Moorman AV, Harrison CJ, Buck GA, et al: Karyotype is an independent prognostic
terized by the deletion of Ikaros. Nature 453:110, 2008. factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from
57. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis in acute lympho- patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooper-
blastic leukemia. N Engl J Med 360:470, 2009. ative Oncology Group (ECOG) 2993 trial. Blood 109:3189, 2007.

Kaushansky_chapter 91_p1505-1526.indd 1522 9/21/15 12:20 PM